Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02747407 · ClinicalTrials.gov registry record
Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
A clinical trial of Glioma and Astrocytoma, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 55
- Enrollment target
- 1
- Study location
NCT02747407: Completed study of Glioma and Astrocytoma, sponsored by Wake Forest University Health Sciences.
NCT02747407 is a study of Glioma and Astrocytoma that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 55 participants, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02747407, a study of Glioma and Astrocytoma, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This research trial studies qualitative, qualitative, and functional studies over the first year in measuring immune system response in patients with brain tumors. Measuring the number of immune cells, whether these immune cells work correctly, and response to 2 vaccines at several times during the first year of treatment may help find out how active the immune system responds to fight infection and cancer.
Primary Outcome
Mean values of the quantitative measures and proliferative ability will be calculated for each four time points and compared to determine the trajectory over time as described. In addition, the repeated measures for quantitative measures will be displayed graphically with individual trajectories. The linear mixed model will be performed to identify predictors (e.g., sex) that are associated with the quantitative measures. Furthermore, the generalized estimating equations model with the logit lin
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Trivalent Influenza Vaccine
- BIOLOGICAL Tetanus Toxoid Vaccine
- BIOLOGICAL Hepatitis A Vaccine
Study Locations (1)
North Carolina
- Comprehensive Cancer Center of Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2016-05 |
| Est. Completion | 2021-09-09 |
What the finished NCT02747407 record still lists
NCT02747407 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (74% lower).
The record links to 3 conditions, with Glioma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02747407 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02747407 about?
NCT02747407 is a clinical study titled "Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors". This research trial studies qualitative, qualitative, and functional studies over the first year in measuring immune system response in patients with brain tumors. Measuring the number of immune cells, whether these immune cells work correctly, and response to 2 vaccines at several times during the ...
What is the current status of trial NCT02747407?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2016-05. Estimated completion is 2021-09-09.
What conditions does trial NCT02747407 study?
This clinical trial studies the following conditions: Glioma, Astrocytoma, Oligodendroglioma.
What interventions are being tested in trial NCT02747407?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Trivalent Influenza Vaccine (BIOLOGICAL), Tetanus Toxoid Vaccine (BIOLOGICAL), Hepatitis A Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02747407?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02747407 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02747407's enrollment target sits among peer trials
55 34th of 87 higher than 52 of 87 other Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Tumor Treating Fields for the Treatment of Brainstem Gliomas
RECRUITING · NA
-
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RECRUITING · Phase 4
-
Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks
RECRUITING
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
- NCT03317158 · 55 participants · Phase 1
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia